Mesoblast Limited has secured a new five-year credit facility of up to US$125 million from existing shareholder and director Dr. Gregory George, replacing its previous senior secured loan from Oaktree Capital Management and partially repaying its subordinated royalty facility from NovaQuest Capital Management. The initial US$75 million draw carries a fixed interest rate of 8% per annum, significantly lower than Mesoblast's prior debt arrangements, and features an interest-only period for the full five years. The facility is initially unsecured and does not encumber any of Mesoblast's material assets or intellectual property. An additional US$50 million tranche is available at Mesoblast’s option until June 30, 2026. The agreement also allows for early repayment without penalties and includes the issuance of five-year warrants to Dr. George, subject to shareholder approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9618020-en) on December 29, 2025, and is solely responsible for the information contained therein.